About Anamar
About Anamar

Overview

AnaMar AB, a Swedish-based drug discovery company, is developing orally bioavailable, peripherally acting 5-HT2B receptor antagonists designed to prevent pathological fibrotic processes. The company is operative in discovery and the early phases of drug development, from the idea stage to clinical trials. This includes invention and optimization of new drug candidates, evaluation of preclinical efficacy and safety and finally, confirmatory early clinical studies in patients with fibrotic disease.

AnaMar’s recently selected candidate drug AM1476 is currently in late preclinical phase and, whilst with potential for application as a treatment across a range of fibrotic diseases, is focused on the treatment of systemic sclerosis. Other potential fibrosis indications include e.g. lung, liver and kidney fibrosis.

AnaMar AB is a privately held company.